-60%

est. 2Y upside i

HealthcareSeries A

Robotic human cell manufacturing

Rank

#500

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Low

Mytos presents a moderate upside opportunity for a job seeker, driven by its innovative automated cell manufacturing platform addressing a large and growing market ($82.1B TAM, ~17% YoY growth).

Last updated: March 10, 2026

Bull (25%)+350%

Mytos's automated platform and CDMO services achieve rapid market penetration in regenerative medicine, securing major partnerships and expanding its customer base significantly. This drives revenue to over $100M by 2028, justifying a $360M+ valuation at a premium multiple due to its unique technology and critical role in scaling cell therapies.

Base (45%)+120%

Mytos successfully executes on its current strategy, growing steadily within its target market segments and expanding its CDMO offering. It captures a meaningful share of the automated cell manufacturing market, reaching approximately $50M in revenue by 2028 and achieving a valuation of around $176M, reflecting solid execution in a high-growth sector.

Bear (30%)-85%

Mytos faces intense competition from incumbents or struggles with the high capital intensity and regulatory hurdles inherent in the biotech sector. Revenue growth is slower than anticipated, leading to further significant dilution in a down round or a low-value acquisition, resulting in a valuation of $12M or less, severely impacting common stock value due to liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $24M in liquidation preferences ahead of common stock, representing 30% of the estimated current $80M valuation. In an $80M exit, common shareholders would only see returns after the $24M preference is paid.

Dilution Risk

moderate

As a Series A company in a capital-intensive sector, Mytos will likely require several more funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Mytos's equity at this early stage.

Any — 1 role

Biology — 1 role

CDMO — 1 role

Operations — 1 role

Product — 1 role

View all 8 open roles at Mytos →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Mytos's data — designed to show you've done your homework.

  • 1

    “Mytos's fluidic-based automation system offers a differentiated approach compared to robotic arm solutions used by some competitors. How do you plan to maintain and strengthen this competitive moat against larger incumbents like Miltenyi Biotec and Sartorius Stedim Biotech, especially as they might invest more heavily in similar technologies or acquisitions?”

  • 2

    “The company operates in a high capital intensity and highly regulated space. What are the key milestones and financial metrics Mytos is focused on achieving in the next 18-24 months to demonstrate scalable revenue generation and manage burn rate effectively, particularly as you expand your CDMO services?”

  • 3

    “Given the Series A funding and the preference stack, what is the company's philosophy on future funding rounds and potential liquidity events for employees? Are there any plans for secondary liquidity or tender offers as the company matures?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.